Home / Generics / News / Dr Reddy’s to buy US generics from Teva

Dr Reddy’s to buy US generics from Teva Posted 17/06/2016

Generics giant Dr Reddy’s Laboratories (Dr Reddy’s) announced on 11 June 2016 that it had made a deal with Teva Pharmaceutical Industries (Teva) and an affiliate of Allergan to acquire a portfolio of eight abbreviated new drug applications (ANDAs) in the US.

The agreement is reported to be costing Dr Reddy’s US$350 million. The deal comes as part of a requirement from US authorities in order to approve Teva’s acquisition of Allergan’s generics business [1]. The acquisition is therefore contingent on the closing of the Teva/Allergan generics transaction and approval by the US Federal Trade Commission of Dr Reddy’s as a buyer.

The products being acquired were not divulged. However, they are reported to consist of a mix of filed ANDAs pending approval and an approved ANDA, and are comprised of complex generics across diverse dosage forms.

The products will help Dr Reddy’s ‘create new opportunities for growth’ in the US, according to GV Prasad, Co-Chairman and CEO of Dr Reddy’s Laboratories. The company has over 79 filed ANDAs pending approval, of which it believes 18 have first-to-file status.

Related article
Dr Reddy’s buys six OTC brands from Ducere Pharma

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Teva acquires Mexican drugmaker Rimsa [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Jun 17]. Available from: www.gabionline.net/Pharma-News/Teva-acquires-Mexican-drugmaker-Rimsa

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.

Source: Dr Reddy’s

Comments (0)

Generics News Research General

more

Biosimilars News Research General

more